ARTICLE | Preclinical News
Foghorn co-founder shows chromatin remodeling inhibition could treat sarcoma
November 6, 2018 12:13 AM UTC
Dana-Farber Cancer Institute researchers, including Foghorn Therapeutics Inc. (Cambridge, Mass.) co-founder Cigall Kadoch, and colleagues suggested inhibitors of the chromatin remodeling non-canonical BAF complex (ncBAF) could help treat sarcomas.
Three SWI/SNF complexes with distinct but overlapping protein subunits regulate chromatin remodeling and help establish stable, cell-specific gene expression patterns: canonical BAF (cBAF); polybromo-associated BAF (PBAF); and the recently identified ncBAF complex...
BCIQ Target Profiles